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ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2004.06.048Objective: Complement activation has been shown to play a significant role in
ischemia-reperfusion injury after lung transplantation. TP-10 (soluble complement
receptor 1 inhibitor) inhibits the activation of complement by inactivating C3a and
C5a convertases. This was a clinical trial of TP-10 to reduce ischemia-reperfusion
injury in lung transplantation.
Methods: In a randomized, double-blinded, multicenter, placebo-controlled trial, 59
patients from four lung transplant programs received TP-10 (10 mg/kg, n  28) or
placebo (n  31) before reperfusion. This dose achieved 90% complement inhibi-
tion for 24 hours, and activity had returned toward normal by 72 hours.
Results: At 24 hours, 14 of 28 patients in the TP-10 group (50%) were extubated,
whereas only 6 of 31 patients in the placebo group (19%) were (P  .01). The total
times on the ventilator and in the intensive care unit both tended to be shorter in the
TP-10 group, but these differences did not achieve statistical significance. Among
patients requiring cardiopulmonary bypass (n  5 in placebo group and n  7 in
TP-10 group), the mean duration of mechanical ventilation was reduced by 11 days
in the TP-10 group (10.6  5.0 days vs 21.5  5.9 days in placebo group, P  .2).
Operative deaths, incidences of infection and rejection, and length of hospital stay
were not significantly different between the two groups.
Conclusions: Short-term complement inhibition with TP-10 led to early extubation
in a significantly higher proportion of lung transplant recipients. The effect of TP-10
was greater among patients undergoing cardiopulmonary bypass, with a large
reduction in ventilator days. Complement inhibition thus significantly decreases the
duration of mechanical ventilation and could be useful in improving the outcome of
lung transplant recipients.
Lung transplantation has become a standard therapy for patients withend-stage lung disease. More than 15,000 lung transplantations havebeen performed worldwide, and approximately 1500 are performedevery year.1 Despite the recent expansion both in the number ofcenters performing lung transplantation and in the number of pa-tients undergoing transplantation, ischemia-reperfusion (IR) injury
remains an important problem after lung transplantation.2,3 It occurs in as many as
10% to 20% of patients, despite the recent introduction of low-potassium dextran
solution (Perfadex; Vitrolife, Goteborg, Sweden) to preserve the lungs, and still
represents the prime cause of early morbidity and mortality.4 In addition, there is
The Journal of Thoracic and Cardiovascular Surgery ● Volume 129, Number 2 423
Cardiothoracic Transplantation Keshavjee et al
TXsome evidence to suggest a relationship between IR injury
and both acute rejection and chronic graft dysfunction.5,6
Prediction of early lung dysfunction has been difficult
because of the complexity of the interactions between the
donor lung and the recipient.7 A large number of interven-
tions have been performed experimentally to limit the re-
lease of inflammatory mediators and to improve the quality
of the lung.8 However, relatively few treatment options
have been translated into clinical practice.9
Complement is a collective term used to describe a group
of plasma and cell membrane proteins that play a key role in
the cell defense process.10 Animal experiments have shown
that activation of the complement system may lead to cel-
lular injury through direct and indirect mechanisms during
lung ischemia and reperfusion.11,12 Complement receptor 1
is a natural complement antagonist that has been cloned and
the transmembrane portion removed to obtain a soluble
form (sCR1). sCR1 can suppress both the classic and the
alternative pathways of complement activation by inhibiting
C3 and C5 convertases. We and others have shown in a
swine single-lung transplantation model that the adminis-
tration of sCR1 to the recipient before reperfusion signifi-
cantly reduces lung edema and improves lung function.13,14
In response to these results, we undertook a multicenter trial
to evaluate whether complement inhibition with sCR1 (TP-
10) would lead to reduced IR injury and improved outcomes
in human lung transplantation.
Materials and Methods
We performed a randomized, double blind, placebo-controlled trial
at four North American lung transplant centers. These centers were
the University of Toronto, Duke University, the University of
Colorado, and Washington University. The study drug and placebo
TABLE 1. Patient characteristics
TP-10
(n  28)
Placebo
(n  31) P value
Age (y)
Mean  SEM 53.4 10.5 51.8 7.8 .5
18-60 (No.) 24 28 .6
60 (No.) 4 3
Sex (No.) .6
Male 19 19
Female 9 12
Lung transplantation (No.) .7
Single 16 16
Bilateral 12 15
Pathology (No.) .8
Emphysema 19 20
Pulmonary fibrosis 3 6
Pulmonary hypertension 4 4
Other 2 1were provided by T Cell Sciences Inc. Patients with end-stage
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enrolled in the trial. Patients with cystic fibrosis or with infectious
conditions such as bronchiectasis were excluded from the study
because of the theoretic possibility that complement inhibition
might impair the ability to fight infection. All patients received
standard care, including immunosuppressive therapies, antirejec-
tion therapies, and anti-infection therapies, as determined by the
principal investigator at each institution. Pharmacists in each cen-
ter randomly assigned patients at the time of transplantation and
provided drug or placebo in a blinded fashion. Lung preservation
methods were similar between the centers, with a bolus of 500 g
prostaglandin E1 followed by an anterograde flush of Euro-Collins
solution injected through the pulmonary artery and hypothermic
preservation during transport.
A total of 59 patients enrolled in the study were randomly
assigned to either the TP-10 group (n  28) or the placebo group
(n  31). One patient was excluded because of incomplete dose
administration. One patient received placebo instead of the drug
and was perforce transferred to the placebo group. There was no
significant difference between groups in age, sex, type of trans-
plantation, and underlying lung disease (Table 1). The drug was
administered at a dose of 10 mg/kg through a period of 30 minutes
before reperfusion of the first allograft. This dose has been shown
to achieve 90% complement inhibition for 24 to 48 hours, with
a return to normal activity by 72 hours.15
The primary end point was the time to extubation. We consid-
ered the duration of mechanical ventilation to be a clinically
important end point for a phase III study, because it reflects the
severity of IR injury, intensive care unit (ICU) morbidity, and
resource use. Secondary end points were as follows: PaO2/inspired
oxygen fraction ratio, ICU and hospital stays, and survival. Chest
radiographs performed on postoperative day (POD) 1, POD 2, and
POD 3 were blindly reviewed by a radiologist, and scores of 0 to
5 were attributed to the upper, middle, and lower zones of each
transplanted lung. A score of 0 defined a clear chest radiograph,
and a score of 5 was given when the entire zone was consolidated.
The total score (0-15 for each lung) was multiplied by 2 for
patients with single-lung transplants. The incidences of acute re-
jection and infection were also recorded. Safety parameters and
pharmacokinetics of the drug were also analyzed. All surviving
patients were prospectively followed up for 6 months after the
transplantation.
Assessment of Complement Activity
The inhibitory effect of TP-10 on the complement system was
determined by the Mayer hemolysis method to measure comple-
ment activity (CH50) and by the level of C3a in the blood, as
described previously elsewhere.13 To carry out these assays, blood
was collected before administration of the drug and at 12, 24, 48,
and 72 hours after reperfusion, as well as on the POD 5.
Statistical Analysis
Data collection and management was carried out by T Cell Sci-
ences. All data analysis was supervised by the principal investi-
gators (S.K., R.D.D., M.R.Z., G.A.P.). Results are expressed as
mean  SEM. Categoric variables were analyzed by Fisher exact
test or 2 test, and continuous variables were analyzed by Student
t test. Repeated-measures analysis of variance and planned com-
uary 2005
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and CH50 values after reperfusion.
Results
Complement Activity
Complement activity was in fact reduced during the initial
24 to 72 hours after reperfusion in both the placebo and
TP-10 groups. However, complement activity was reduced
by a maximum of 45% in the control group, whereas it was
reduced by as much as 90% in the TP-10 group (Figure 1).
The level of C3a decreased during the initial 72 hours after
reperfusion in the TP-10 group, whereas it increased imme-
diately after reperfusion in the placebo group (Figure 2).
After 5 days, the complement activity and the level of C3a
were back to similar values in both the placebo and TP-10
groups (Figures 1 and 2).
Mortality
A total of 5 patients died in the early postoperative period
(28 days), 2 (7.1%) in the TP-10 group and 3 (9.7%) in the
control group (P  .1). In addition, 7 patients died between
1 and 6 months after the operation, 5 (19.2%) in the TP-10
group and 2 (7.1%) in the control group (P  .2; Table 2).
Postoperative Results
Although the PaO2/inspired oxygen fraction ratio on arrival
at the ICU was not significantly different between the two
groups, TP-10 led to a significant increase in the rate of
early extubation. At 24 hours, 14 of 28 patients in the TP-10
group (50%) were extubated, whereas only 6 of 31 patients
in the control group (19%) were extubated (P  .01). The
total duration of mechanical ventilation tended to be shorter
in the TP-10 group, but this finding did not achieve statis-
tical significance (8.2  2.9 days in TP-10 group vs 13.1 
3.2 days in control group, P  .3). If patients who died
during ventilation were excluded, however, the total time on
the ventilator was indeed significantly shorter in the TP-10
group (6.4  2.3 days in TP-10 group vs 16.3  3.7 in
control group, P  .03). There were no significant differ-
Figure 1. Complement inhibition in lung transplantences in ICU and hospital stays between the two groups
The Journal of Thoraci(Table 3). There were no significant difference in the chest
radiograph score between the two groups on POD 1 (10 
7 in TP-10 group vs 9  7 in placebo group, P  .6), POD
2 (11  7 in TP-10 group vs 12  7 in placebo group, P 
.6), and POD 3 (11 6 in TP-10 group vs 12 8 in placebo
group, P  .5).
Cardiopulmonary Bypass
A total of 12 patients required cardiopulmonary bypass
(CPB). There were 7 patients in the TP-10 group (25%) with
a mean CPB time of 3.3  1.2 hours and 5 patients in the
control group (16%) with a mean CPB time of 4.2  0.4
hours. The mean duration of mechanical ventilation was
reduced by 11 days in the TP-10 group (10.6  5.0 days in
TP-10 group vs 21.5  5.9 days in control group, P  .2),
and the ICU stay was reduced by 6 days (16.4  5.4 days
in TP-10 group vs 22.4 6.4 days in control group, P .5).
Episodes of Infection and Rejection
In the TP-10 and control groups, 41 and 64 infectious
episodes, respectively, occurred within 6 months after sur-
gery (P not significant). Among them, 18 in the TP-10
group and 29 in the control group occurred in the early
postoperative period (28 days, P not significant). Twenty-
two patients in each group had at least one episode of
rejection. The total numbers of rejection episodes were 34 in
the TP-10 group and 32 in the control group (P not signif-
icant).
Discussion
IR injury is a complex process that involves the release of
several mediators, leading to tissue injury and to the infil-
tration of inflammatory cells such as lymphocytes and neu-
trophils.16 The infiltrating inflammatory cells can perpetuate
the initial inflammatory reaction and induce further injuries.
Recent studies have recognized the predominant role of
mediators such as cytokines, adhesion molecules, platelet-
activating factor (PAF), leukotrienes, P-selectin, and endo-
. Effect of TP-10 on CH50 values after reperfusion.thelin.8 The complement system is an important mediator of
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course of IR injury.11,12 Furthermore, it is considered to be
the first link between the innate and acquired immune
systems.17
Activation of the complement cascade results in the
release of several biologically active products, such as C3a
and C5a, also called anaphylatoxins, and the formation of
the membrane attack complex C5b-C9.10 C5b-C9 is a mac-
romolecular complex capable of forming a channel through
the plasma membrane, which directly causes target cell
lysis. C5b-C9 can also upregulate adhesion molecules, stim-
ulate the release of PAF and cytokines, and promote the
procoagulant properties of endothelium.18 C5b-C9 has been
reported to be the main mediator of complement-induced
injury in a mouse model of warm ischemia of the kidney.18
Complement factor C5a is a potent neutrophil and lym-
phocyte chemoattractant that is rapidly released after reper-
fusion.19 In animal models of heart ischemia, specific neu-
tralization of C5a or C5a receptor at the time of reperfusion
Figure 2. Complement inhibition in lung transplan
TABLE 2. Causes of mortality in control and TP-10 groups
Patients POD Cause of death Ventilated
Control group
1 9 Primary graft failure Yes
2 14 Sepsis/pneumonia Yes
3 28 Multiple-system organ
failure/sepsis
Yes
4 73 Perforated colon/sepsis No
5 176 Cytomegalovirus No
TP-10 group
1 6 Primary graft failure Yes
2 11 Myocardial infarct Yes
3 57 Duodenal ulcer/sepsis No
4 71 Respiratory failure Yes
5 93 Respiratory syncytial virus
pneumonia
No
6 97 Sepsis No
7 166 Diverticulitis/sepsis Nohas been shown to reduce infarct size and to decrease
426 The Journal of Thoracic and Cardiovascular Surgery ● Febrneutrophil activation and accumulation.19-22 The effect of
C5a and C3a inhibition has not been directly demonstrated
in lung transplantation. However, the intrabronchial instil-
lation of C3a, C5a, or both in guinea pigs has been shown
to induce acute lung injury, and specific C5a inhibition has
been shown to reduce acute lung injury induced by immu-
noglobulin G immune complexes or by intestinal IR
injury.23-25
Inhibition of the complement system with sCR1 prevents
the release of anaphylatoxins and the formation of the
complex C5b-C9.26 The administration of sCR1 before
reperfusion has been shown to reduce IR injury experimen-
tally in a number of organs, such as the lung, heart, liver,
and intestine.13,14,27-29 To the best of our knowledge, this
study is the first report of administration of sCR1 in clinical
lung transplantation. The study was a multicenter, random-
ized, double-blind, placebo-controlled trial that included a
total of 59 patients undergoing lung transplantation. In it,
short-term complement inhibition at the time of reperfusion
led to early extubation in a significantly higher proportion of
n. Effect of TP-10 on C3a levels after reperfusion.
TABLE 3. Postoperative results
TP-10
(n  28)
Placebo
(n  31) P value
Ischemic time (h)* 4.4 0.3 4.0 0.3 .4
PaO2/inspired oxygen
fraction (mm Hg)†
345 34 378  38 .5
Early extubation (No.) 14 6 .01
Intubation (d) 8.2 2.9 13.1 3.2 .3
Intubation among
survivors (d)‡
6.4  2.3 16.3 3.7 .03
ICU stay (d) 12.5 3.1 14.8  4.4 .7
Hospital stay (d) 33.4 5.4 30.8  4.8 .7
Data represent mean  SEM except as noted.
*Ischemic times from the second lung were used for bilateral transplants.
†On arrival to ICU.
‡Excluding patients who died during ventilation (n  3 in each group).patients; that is, the number of patients extubated within the
uary 2005
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more than double that in the control group.
Although patients’ ventilation protocols were not stan-
dardized among the centers, the finding that 50% of the
patients in the TP10 group were extubated within 24 hours,
whereas only 19% in the placebo group were, is a striking
difference that is unlikely to have been observed by chance
alone. In addition, the median time to extubation was sim-
ilar between centers, and three of the centers tended to have
a shorter time to extubation in the TP-10 group.
The effect of complement inhibition was greater in the
subgroup of patients undergoing CPB. We observed a re-
duction of 11 days in the mean duration of mechanical
ventilation and of 6 days in the mean ICU stay relative to
the control group. Although the difference was not statisti-
cally significant because of the small number of patients, the
clinical significance of this drug effect is potentially impor-
tant. Patients requiring CPB have a double-hit injury, IR and
CPB. Thus the benefit of complement inhibition in this
subset of patients is likely to be much greater.
Two other double-blind, placebo-controlled, randomized
trials have been completed in lung transplantation in an
attempt to reduce the degree of IR injury, and neither
showed striking differences. Wittwer and colleagues30 re-
ported the effect of a PAF antagonist in 24 patients under-
going bilateral lung transplantation and found a tendency
toward better oxygenation during the initial 24 hours after
reperfusion in the two groups of patients treated with PAF
antagonists than in the control group. In a double-blind,
placebo-controlled, randomized trial studying the effect of
prophylactic inhaled nitric oxide on IR injury in more than
80 patients,31 no differences in immediate oxygenation,
time to extubation, stay in the ICU, and 30-day mortality
were observed between the two groups. That study demon-
strated that despite the apparently valuable clinical role of
nitric oxide in the treatment of established IR injury, inhaled
nitric oxide does not appear to prevent the development of
IR injury.
The redundancy of the innate immune system makes it
difficult to reduce IR injury by inhibiting only one pathway,
such as the complement system. Thus several authors have
recently reported on the effects of combined inhibitors of
the innate immune system. Schmid and coworkers32 have
shown that dual strategies, such as associating sCR1 with
sialyl Lewis X, a potent ligand for selectin adhesion mole-
cules inhibiting neutrophil migration, can have a cumulative
beneficial effect. The combination of sCR1 and sialyl Lewis
X improved lung function and reduced neutrophil migration
as well as lipid peroxidation relative to sCR1 alone.33 Mod-
ulation of more than one pathway of IR injury seems to be
a promising strategy that remains to be validated in future
clinical trials.
The Journal of ThoraciIn summary, we have shown that TP-10 decreases the
magnitude of IR injury after lung transplantation in human
beings. A significantly greater number of patients treated
with the drug were extubated within 24 hours after trans-
plantation. Importantly, this study underscores the impor-
tance of multicenter trials to answer important questions in
lung transplantation. The strength of this study lies in the
fact that it represents a randomized, double-blind, placebo-
controlled, clinical trial in IR injury after lung transplanta-
tion. Even with the involvement of four large lung trans-
plant centers, however, this study was still relatively
underpowered to be able to statistically demonstrate impor-
tant differences. With the development of novel agents for
the modulation of lung preservation and IR injury, larger
multicenter cooperative trials will be required to critically
appraise the value of their translation into clinical applica-
tion.
We acknowledge Una S. Ryan and James L. Levin from T Cell
Sciences Inc for their assistance in carrying out this study.
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